Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer

키워드

참고문헌 (60)

1. Heemskerk B, "The cancer antigenome", EMBO J, 32, pp.194~203 (2013)
2. Schumacher TN, "Neoantigens in cancer immunotherapy", Science, 348, pp.69~74 (2015)
3. Alexandrov LB, "Signatures of mutational processes in human cancer", Nature, 500, pp.415~421 (2013)
4. Loi S, "Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer : results from the FinHER trial", Ann Oncol, 25, pp.1544~1550 (2014)
5. Mahmoud SM, "Tumor-infiltrating CD8+lymphocytes predict clinical outcome in breast cancer", J Clin Oncol, 29, pp.1949~1955 (2011)
6. Menard S, "Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas", Clin Cancer Res, 3, pp.817~819 (1997)
7. Mohammed ZM, "The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer", Br J Cancer, 107, pp.864~873 (2012)
8. Tomsova M, "Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma", Gynecol Oncol, 108, pp.415~420 (2008)
9. Zhang L, "Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer", N Engl J Med, 348, pp.203~213 (2003)
10. de Jong RA, "Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer", Gynecol Oncol, 114, pp.105~110 (2009)
11. Giatromanolaki A, "The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer", Gynecol Oncol, 110, pp.216~221 (2008)
12. Ino K, "Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival", Clin Cancer Res, 14, pp.2310~2317 (2008)
13. Kondratiev S, "Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma", Clin Cancer Res, 10, pp.4450~4456 (2004)
14. Yamagami W, "Immunofluorescencedetected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer", Int J Gynecol Cancer, 21, pp.1628~1634 (2011)
15. Taube JM, "Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy", Clin Cancer Res, 20, pp.5064~5074 (2014)
16. Galon J, "The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures", Immunity, 39, pp.11~26 (2013)
17. Coussens LM, "Leukocytes in mammary development and cancer", Cold Spring Harb Perspect Biol, 3, pp.a003285~ (2011)
18. Gobert M, "Regulatory T cells recruited through CCL22", CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome, 2009, pp.69, 2000~2009
19. Gu-Trantien C, "CD4(+)follicular helper T cell infiltration predicts breast cancer survival", J Clin Invest, 123, pp.2873~2892 (2013)
20. Ruffell B, "Leukocyte composition of human breast cancer", Proc Natl Acad Sci U S A, 109, pp.2796~2801 (2012)
21. Cimino-Mathews A, "Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors : a pilot study", Hum Pathol, 44, pp.2055~2063 (2013)
22. Gutcher I, "APC-derived cytokines and T cell polarization in autoimmune inflammation", J Clin Invest, 117, pp.1119~1127 (2007)
23. Abbas AK, "Regulatory T cells : recommendations to simplify the nomenclature", Nat Immunol, 14, pp.307~308 (2013)
24. Liu S, "CD8+lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer", Breast Cancer Res, 14, pp.R48~ (2012)
25. Seo AN, "Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer", Br J Cancer, 109, pp.2705~2713 (2013)
26. Liu F, "CD8(+)cytotoxic T cell and FOXP3(+)regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes", Breast Cancer Res Treat, 130, pp.645~655 (2011)
27. Teschendorff AE, "Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules", BMC Cancer, 10, pp.604~ (2010)
28. Qi W, "Correlation between Th17 cells and tumor microenvironment", Cell Immunol, 285, pp.18~22 (2013)
29. Bates GJ, "Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse", J Clin Oncol, 24, pp.5373~5380 (2006)
30. West NR, "Tumour-infiltrating FOXP3(+)lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer", Br J Cancer 2013;, 108, pp.155~162 (2013)
31. Anz D, "In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype", Histopathology, 59, pp.965~974 (2011)
32. Miyashita M, "Tumor-infiltrating CD8+and FOXP3+ lymphocytes in triple-negative breast cancer : its correlation with pathological complete response to neoadjuvant chemotherapy", Breast Cancer Res Treat, 148, pp.525~534 (2014)
33. An T, "In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma : relation to prognostic parameters", Am J Pathol, 128, pp.52~60 (1987)
34. Mahmoud SM, "The prognostic significance of B lymphocytes in invasive carcinoma of the breast", Breast Cancer Res Treat, 132, pp.545~553 (2012)
35. Schmidt M, "A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors", Clin Cancer Res, 18, pp.2695~2703 (2012)
36. Martinet L, "Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer", Cancer Res, 71, pp.5678~5687 (2011)
37. Martinet L, "High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin beta-producing dendritic cells in human breast cancer", J Immunol, 191, pp.2001~2008 (2013)
38. Melichar B, "Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines", Clin Cancer Res, 4, pp.3069~3076 (1998)
39. Jacquemier J, "3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma", Int J Cancer, 130, pp.96~104 (2012)
40. Dong DD, "Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer", Hum Immunol, 73, pp.998~1004 (2012)
41. Hornychova H, "Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma", Cancer Invest, 26, pp.1024~1031 (2008)
42. Denkert C, "Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer", J Clin Oncol, 28, pp.105~113 (2010)
43. Salgado R, "The evaluation of tumor-infiltrating lymphocytes(TILs)in breast cancer : recommendations by an International TILs Working Group 2014", Ann Oncol, 26, pp.259~271 (2015)
44. West NR, "Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer", Breast Cancer Res, 13, pp.R126~ (2011)
45. Loi S, "Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy:BIG 02-98", J Clin Oncol, 31, pp.860~867 (2013)
46. Adams S, "Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials : ECOG 2197 and ECOG 1199", J Clin Oncol, 32, pp.2959~2966 (2014)
47. Liu S, "Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration", Breast Cancer Res, 16, pp.432~ (2014)
48. Ali HR, "Association between CD8+T-cell infiltration and breast cancer survival in 12,439 patients", Ann Oncol, 25, pp.1536~1543 (2014)
49. Schalper KA, "In situ tumor PD-L1mRNA expression is associated with increased TILs and better outcome in breast carcinomas", Clin Cancer Res, 20, pp.2773~2782 (2014)
50. Perez EA, "Stromal tumor-infiltrating lymphocytes (S-TILs): in the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit", San Antonio Breast Cancer Symposium (SABCS) (2014)
51. Denkert C, "Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers", J Clin Oncol, 33, pp.983~991 (2015)
52. Ono M, "Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer", Breast Cancer Res Treat, 132, pp.793~805 (2012)
53. Yamaguchi R, "Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer", Hum Pathol, 43, pp.1688~1694 (2012)
54. Oda N, "Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU", epirubicin, Breast Cancer Res Treat, pp.2012, 136[DOI]
55. Issa-Nummer Y, "Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial", PLoS One, 8, pp.e79775~ (2013)
56. 이희진, "Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients", Journal of Breast Cancer, 16(1), pp.32~39 (2013), 한국유방암학회[DOI]
57. Nabholtz JM, "Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline", taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact, 2014, pp.25, 1570~1577
58. Shah SP, "The clonal and mutational evolution spectrum of primary triple-negative breast cancers", Nature, 486, pp.395~399 (2012)
59. Perez EA, "Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial", J Clin Oncol, 33, pp.701~708 (2015)
60. Mao Y, "The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and metaanalysis", PLoS One, 9, pp.e115103~ (2014)

관련 논문AI추천